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Abstract 
Introduction: Parkinson’s disease (PD) is a neurodegenerative disease that affects the dopaminergic 
neurons via neuroinflammatory response activated by the presence of alpha-synuclein Lewy bodies. 
Current treatment of PD include small molecule therapy for symptomatic treatment, warranting the need 
of novel treatment options that can delay disease progression such as neurotropic factors like glial cell-
line derived neurotropic factor (GDNF). One major barrier for delivery of such therapy is the blood-brain-
barrier which will be bypassed by using macrophage-derived exosomes for drug delivery. Previous 
studies have used acute inflammation models for PD; however, because PD involves mild inflammation 
in earlier disease stages, transgenic murine model will be assessed to better model PD in humans.  
Methods: Transgenic mice with mutant Parkin gene (Parkin-Q311X) were treated with transfected 
macrophages containing GDNF at 4 months. At 16 months, the behavioral tests were performed. The 
animals were then sacrificed, perfused, and fixed. Ten micron sections were cut and stained with anti-
alpha synuclein and anti-GFAP antibodies to assess the Lewy body and astrocytosis status.  
Results: Imaging 4 hours post-IV administration of macrophages shows accumulation of macrophages 
in the PD brain in comparison to no accumulation in wild-type brain. The presence of alpha-synuclein 
Lewy bodies was significantly lower (p < 0.05) in PD mice that were treated with GDNF-macrophages 
compared to PD mice treated with sham-macrophages and PBS. Astrocytosis was also significantly lower 
(p < 0.05) in PD mice treated with GDNF-macrophages compared to PD mice treated with sham-
macrophages and PBS. 
Conclusion: Treatment with GDNF-transfected macrophages improved survival of dopaminergic neurons 
in transgenic murine model of PD consistent with results from acute neurotoxin-induced inflammation PD 
models. This treatment also lowers the presence of the alpha-synuclein Lewy bodies that increase 
neuroinflammation ultimately leading to neurodegeneration and reduces astrocytosis. 
 







Parkinson’s Disease (PD) is a neurodegenerative disease that affects approximately 1 million 
people in the United States that is more prevalent with the older generation than the young.1 The disease 
primarily presents with motor symptoms such as bradykinesia/akinesia, rigidty, and resting tremors that 
are attributed to degeneration of dopaminergic neurons of the substantia nigra pars compacta (SNc) that 
project to the striatum.2,3 This degeneration is attributed to activation of the neuroinflammatory response 
due to the presence Lewy bodies.4,5 The Lewy bodies are aggregates of the endogenous protein alpha-
synuclein that is mostly found in the presynaptic terminals of neurons as well as extracellular fluid.4 These 
abnormal aggregates lead to inflammation which in turn activates microglia.4,5 This leads to the the 
release of reactive oxygen species that ultimately leads to neurodegeneration of these dopaminergic 
neurons.3-6  
Current standard of treatment for PD consists of small molecule drug therapy, such as carbidopa-
levodopa, monoamine oxidase-B inhibitor, catechol-O-methyltransferase inhibitor, anticholinergic agents, 
and dopamine agonists, that only provides symptomatic treatment of PD, endorsing the need for novel 
treatment options.7 While younger patients are able to receive other options such as dopamine agonists, 
carbidopa-levodopa is the standard and essentially the sole option for patients over the age of 65.7,8 
Levodopa is a precursor to dopamine and provides replacement therapy for the depleted dopamine that 
is no longer being released by the degenerated dopaminergic neurons.9 This dopamine replacement 
therapy helps alleviate motor symptoms of PD but comes with adverse effects such as dyskinesia.7,9 
Anticholinergic agents are used to treat the tremors associated with PD, but they aren’t recommended in 
older patients due to increased adverse effects.7,8  
Glial cell-line derived neurotropic factor (GDNF) is primarily responsible for the survival and 
maintenance of dopaminergic and motor neurons.10,11 Even in healthy models, lack of GDNF decreases 
dopaminergic neuron survival.10 While GDNF seems promising for treatment of PD, there is one major 
hurdle for its delivery to the SNc, the blood-brain barrier (BBB). One way to bypass BBB is via the use of 
nanoformulations, but these are easily picked up by mononuclear phagocyte system (MPS) clearing them 
from the body before reaching the SNc.6,12 PEGylated systems have been used to bypass MPS, but 
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PEGylated systems have their own set of issues such as the formation of anti-PEG antibodies that 
increase clearance from the body.6 However, the pathophysiology of PD involves activation of neuronal 
immune response via microglia, which can allow BBB to become more fluidic in order to recruit more 
mononuclear phagocytes, such as macrophages, to the site of inflammation.12 Macrophages carry 
exosomes which facilitate transfer of many different agents such as proteins and RNA.3,6 This natural 
process can be exploited for successful drug delivery to SNc. 
Previous studies have used acute inflammation models of PD using neurotoxins such as 6-
hydroxydopamine (6-OHDA) to observe the effectiveness of macrophages for delivery of therapeutic 
proteins such as GDNF and catalase.3,6,14-20 Acute inflammation models later stage of PD where 
significant neuroinflammation and neurodegeneration are evident. However, the pathophysiology of PD 
involves chronic inflammation with mild inflammation in earlier stages, rather than the acute inflammation 
studied, which could limit the chemotaxis of the macrophages to the site of inflammation for early 
treatment of PD.13 As a result, this study aims to utilizes mild inflammation models of PD via use of 
transgenic mice to assess the effectiveness of macrophage-derived drug delivery of GDNF in PD.  
Results  
Accumulation of Macrophages  
Imaging 4 hours after IV administration of luciferase-labeled macrophages shows accumulation 
of macrophages in the brain of PD mouse in comparison to the no accumulation of macrophages in the 
brain of the matched wild-type mouse (Figure 1A). Even at 6 hours post-administration when the animal 
was sacrificed and the major organs (brain, liver, lungs, spleen, and kidneys) were imaged, there are still 
detectable levels of macrophages in the brain (Figure 1B). Macrophage accumulation can also be 
observed in vital organs such as the liver, spleen, and kidneys. Major organs such as the liver, spleen, 
and kidneys also have an accumulation of macrophages following IV administration of macrophages. 
Even at 6 hours post-administration, highest accumulation of Celesence-loaded macrophages was 




Figure 1. Accumulation of macrophages. IV administration of luciferase-encoded macrophages shows 
accumulation of macrophages in the brain of PD mice 4 hours after administration (A). Six hours after 
administration, the mice were sacrificed and perfused to remove excess blood from the brain and other 
major organs. Celsence-loaded macrophages can still be seen at detectable levels in the brain with high 
levels in the liver (B). 
 
Evaluation of Alpha-synuclein Lewy Bodies 
 When staining for alpha-synuclein Lewy bodies, pre-treatment of brain tissues slides with 
proteinase K allowed for the endogenous alpha-synuclein to be wiped out.22 This is best observed with 
the wild-type mice which shows very minimal, if any, alpha-synuclein staining (Figure 2D). Therefore, 
the fluorescent activity observed in Figure 2 represents the alpha-synuclein Lewy bodies that have 
accumulated in the brains of these PD mice (Figure 2A, C). However, in PD mice that were treated with 
GDNF-macrophages, there is a significant reduction in the in the alpha-synuclein Lewy bodies observed 
(Figure 2B). One-way ANOVA test showed a significant difference in the groups (p<0.05, Table 1a), and 
when a Bonferroni corrected pairwise t-test was performed, treatment with GDNF-macrophages had 
significant reduction in alpha-synucelin Lewy body formation compared to treatment with sham-
macrophages and saline (Table 1b). The comparison of GDNF-macrophages treated PD mice and wild-
type mice found no statistically significant difference in accumulation of alpha-synuclein Lewy bodies 
(Table 1b). Treatment with sham-macrophages also had a significant decrease in alpha-synuclein Lewy 
























Figure 2. Treatment with GDNF-macrophages inhibits the formation of alpha-synuclein Lewy 
bodies. PD mice were treated intravenously early in disease at 4 months with PBS (A), GDNF-
macrophages (B), or sham-macrophages (C) once weekly for 3 weeks. Wild-type mice were injected with 
PBS (D). Immunofluorescence was quantified (E). Treatment with GDNF-macrophages show significant 
reduction in alpha-synuclein Lewy bodies with one-way ANOVA test *p < 0.05. Values are mean r SEM 
(n=6). 
 
Table 1a. One-way ANOVA for number of alpha-synuclein fluorescence by group (n=6). 
 Df Sum Sq Mean Sq F Statistic P-value 
Treatment 3 2989.9 996.6 32.01 7.86E-08 
Residuals 20 622.7 31.1   
 
Table 1b Bonferroni corrected pairwise t-test p-values for difference in alpha-synuclein by 
group (n=6). 
 PD/GDNF-Macrophages PD/Sham-Macrophages PD/Saline 
PD/Sham-Macrophages 4.33E-03 - - 
PD/Saline 7.40E-04 1.03E-03 - 
Wild-Type/Saline 1 0.02 3.72E-03 
 
Rotarod Test 
 Treatment with GDNF-macrophages in PD mice resulted in statistically significant preservation of 
motor function as evident by the results of the rotarod test (Figure 3, Table 2). Early treatment with 
GDNF-macrophages at 4 months led to increases in remaining time on the rotarod while treatment with 
sham-macrophages and PBS led to decreases in remaining time (Figure 3). One-way ANOVA test 
showed a significant difference in the groups (p<0.05, Table 2a), and when Bonferroni corrected pairwise 
t-test was performed, treatment with GDNF-macrophages had significant increase in remaining time on 
the rotarod compared to treatment with sham-macrophages and saline (Table 2b). The comparison of 
GDNF-macrophages treated PD mice and wild-type mice found no statistically significant difference in 
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the remaining time on the rotarod, indicating that there is no significant difference in the motor function 
of the two groups (Table 1b). 
 
Figure 3. Treatment with GDNF-macrophages preserves motor function in PD mice. PD mice 
were treated intravenously (2x106 cells/mouse) with GDNF-macrophages (green), sham-macrophages 
(purple), or with PBS (red) weekly for 3 weeks at 4 months. Treatment with GDNF-macrophages 
resulted in significant improvements in time spent on rotarod cylinder. Values are means ± SEM (n=10). 
*p<0.05 **p<0.005 compared to wild-type mice. 
 
Table 2a. One-way ANOVA for rotarod test times by group. (n=10) 
 Df Sum Sq Mean Sq F Statistic P-value 
Treatment 3 83744 27915 14.1 3.62E-05 
Residuals 20 39590 1980   
 
Table 2b. Bonferroni corrected pairwise t-test p-values for difference in rotarod test times. 
(n=10) 
 PD/GDNF-Macrophages PD/Sham-Macrophages PD/Saline 
PD/GDNF Macrophages - 5.00E-04 - 
PD/Saline 2.75E-03 1 - 
Wild-Type/Saline 1 4.80E-04 2.29E-03 
 
Evaluation of Astrocytosis  
Treatment with GDNF-macrophages in PD mice resulted in decreased astrocytosis compared to 
treatment with sham-macrophages or saline (Figure 4 A, B, C). One-way ANOVA test showed a 
significant difference in the groups with (p < 0.05 Table 3a), and when a Bonferroni corrected pairwise t-
test was performed, treatment with GDNF-macrophages had significant reduction in astrocytosis 
compared to treatment with sham-macrophages and saline (Table 3b). Treatment with GDNF-
macrophages also resulted in a significant decrease in astrocytosis compared to wild-type mice (Table 
3b). Although sham-macrophages treatment resulted in significant decrease in alpha-synuclein Lewy 
bodies compared to PBS treatment, this effect was not seen with astrocytosis (p=0.21, Table 3b).   
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Figure 4. Treatment with GDNF-macrophages decreases astrocytosis. PD mice were treated 
intravenously early in disease at 4 months with PBS (A), GDNF-macrophages (B), or sham-macrophages 
(C) once weekly for 3 weeks. Wild-type mice were injected with PBS (D). Immunofluorescence was 
quantified (E). Treatment with GDNF-macrophages show significant reduction in astrocytosis with one-
way ANOVA test *p < 0.05. Values are mean r SEM (n=6). 
 
Table 3a. One-Way ANOVA for astrocytosis by group (n=6). 
 Df Sum Sq Mean Sq F Statistic P-value 
Treatment 3 196338 65446 24.52 8.09E-09 
Residuals 36 96095 2669   
 
Table 3b. Bonferroni corrected pairwise t-test p-values for difference in astrocytosis by group 
(n=6).  
 PD/GDNF-Macrophages PD/Sham-Macrophages PD/Saline 
PD/Sham-Macrophages 1.60E-05 - - 
PD/Saline 6.60E-06 0.21 - 
Wild-Type/Saline 3.10E-04 0.12 1 
 
Discussion 
Previous studies with neurotoxin-induced acute inflammation models of PD have shown 
accumulation of macrophages in the brain, leading to adequate treatment at SNc with therapeutic 
proteins such as GDNF and catalase.3,6,14-20 However, as previously discussed, PD is a disease that 
involves mild inflammation at early disease stage that may be less susceptible to macrophage 
chemotaxis in comparison to the acute inflammation models that represent later disease stage where 
inflammation is higher. As a result, one major aim of the study was to assess the efficacy of macrophage-
based delivery systems in mild inflammation models of PD. This study has shown that macrophages will 
accumulate in the brain of PD mice, compared to wild-type mice that have no accumulation in the brain, 
even with mild inflammation observed in PD.   
B C D A 
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Accumulation of macrophages in the brain at 4 months even with mild neurodegeneration and 
neuroinflammation allows for early treatment of PD with GDNF. Consistent with previous studies with 
acute inflammation models, GDNF treatment has neuroprotective effects as well as motor function 
preservation.3,6,14-17 Treatment with GDNF-macrophages significantly reduced the accumulation of alpha-
synuclein Lewy bodies that are responsible for disease progression, thereby slowing and/or preventing 
further neurodegeneration. Treatment also significantly improved motor functions as evident by the 
rotarod test where GDNF-macrophage treated mice performed significantly better than the PD mice 
treated with sham-macrophages or PBS. In addition, this study also found that treatment with GDNF-
macrophages has prolonged effects since the mice were only treated at 4 months, but motor functions 
were preserved as well as reduction of alpha-synuclein Lewy bodies 1 year post-treatment.  
If this treatment is approved for human use in the future, patients may have less frequent dosing 
since the effects were prolonged in murine models. Less frequent dosing will improve adherence to 
treatment which will lead to better efficacy for the patient. However, since current studies have only been 
in murine models, further research is needed in larger mammals and ultimately clinical trials in order to 
test the safety and efficacy of GDNF-macrophage therapy. This study is one step closer to providing 
novel treatment options that can slow and prevent disease progression rather than the symptomatic 
treatment offered by the current small molecule therapeutics.  
The next steps of this specific project at large will be looking at the effectiveness of GDNF delivery 
from exosomes isolated from macrophages. This will aim to see if GDNF-exosomes that are isolated 
from GDNF-transfected macrophages then systemically administered, have the same ability to 
chemotaxis to site of mild PD inflammation and have the same neuroprotective effects as when GDNF-
transfected macrophages are administered for drug delivery. Effectiveness of other routes of 
administration (intrathecal, intranasal, intraperitoneal) will also be studied in order to maximize the 




Transgenic mice strain with mutant parkin gene (Parkin-Q311X) was purchased from Jackson 
Laboratory (Bar Harbor, ME, USA).21 The mice were bred in-house in accordance with UNC IACUC 
approved protocols. The mice were identified by genotype using PCR to recognize Parkin-Q311X gene 
(Figure 1). The mice were treated beginning at 4 month of age and were sacrificed at 16 months of age. 
The PD mice were subject to 3 different types of treatment administrations: GDNF transfected 
macrophages, sham-macrophages, and PBS with wild-type mice treated with PBS as a control. 
Macrophage dose was 2x106 cells/mouse. The primary endpoint of this study is the alpha-synuclein Lewy 
body status and motor function. Astrocytosis status is a secondary endpoint of the study.  
 
Assessing Accumulation of Macrophages 
At 4 months of age, PD mice were injected intravenously with luciferase-encoded primary 
macrophages (6x106 cells/100 µL/mouse, n=4) or Celesense-loaded macrophages. Celsense-loaded 
macrophages were prepared by incubating fluorocarbon formulation of Celsense (3mg/mL) with the 
primary macrophages for 4 hours. At 4 hours post administration, the mice injected with the luciferase-
encoded macrophages were subject to IVIS imaging by Xenogen IVIS Optical Imagining System. At 6 
hours post administration, the mice injected with Celesense-loaded macrophages were sacrificed and 
perfused to remove blood that potentially has circulating Celesense-loaded macrophages, and the major 
organs where accumulation of macrophages were seen (brain, liver, lungs, spleen, and kidneys) were 
subject to IVIS imaging.  
Immunohistochemistry  
At 16 months, the wild-type and PD mice were sacrificed, perfused, fixed with 4% 






Figure 5. Genotype of Parkin-
Q311X transgenic mice.  
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were obtained using Leica Cryostat CM1850 and stored in -80C. To assess the accumulation of 
proteinase K resistant alpha synuclein Lewy bodies in both wild-type and PD mice, samples were 
permeabilized with 0.3% Triton X-100 in PBS for 20 minutes and washed in PBS x3. Then they were 
incubated with 10 Pg /mL proteinase K for 10 min and washed in PBS x3 to isolate the alpha-synuclein 
aggregates.22 Then they were incubated with the blocking solution (10% normal goat serum, 22.53 mg/mL 
glycine in PBST) for 1 hour. Then they were incubated with anti-alpha synuclein (1:100; Abcam 
ab131508) primary antibody for 48 hours at 4qC and washed in PBS x3. The samples were then 
incubated with goat anti-rabbit IgG H+L (Alexa Fluor 488) (1:200; Invitrogen A-11008) at room 
temperature for 1 hour and washed.  
To assess the extent of astrocytosis in both wild-type and PD mice, the samples were 
permeabilized with 0.3% Triton X-100 in PBS for 20 minutes and washed in PBS x3. Then they were 
incubated with the blocking solution (10% normal goat serum, 22.53 mg/mL glycine in PBST) for 1 hour. 
Then they were incubated with anti-GFAP (1:500; Abcam ab131508) primary antibody for 48 hours at 
4qC and washed in PBS x3. The samples were then incubated with goat anti-rabbit IgG H+L (Alexa Fluor 
488) (1:500; Invitrogen A-11008) at room temperature for 1 hour and washed. The images of the samples 
were obtained using Zeiss LSM 710 Spectral Confocal Laser Scanning Microscope.  
Rotarod Test 
To assess motor coordination, balance, and ataxia, the mice were subject to rotarod test 
beginning at 4 months. The mice were placed on an accelerating rotarod (Ugo Basil) that accelerates to 
a constant speed. The mice were subject to 2 tests conducted within 48 hours of each other consisting 
of 3 trials and 2 trials respectively. Each trial ran for a maximum of 5 minutes or until the mice fell off and 
started with the rotarod set at 5 revolutions per minute (rpm). Then the rpm was increased progressively 
to a max of 30 rpm or until the mice fell off the rotarod. Baseline test was run at 4 months with an endpoint 
of 14 months to assess efficacy of treatment with GDNF-macrophages on motor function.  
Statistical Analysis  
All data points are represented as mean r SEM. For immunohistochemistry, one-way ANOVA 
test was done to see if there is a significant difference between the groups. If there was a significant 
 12 
difference, a post hoc Bonferroni correction pairwise t test was done to evaluate the presence of 
significant difference between each group. For rotarod test, one-way ANOVA test was done to detect a 
difference in scores at baseline and endpoint for the different groups. As with analysis with 
immunohistochemistry, if there was a significant difference, Bonferroni correction pairwise t test was done. 
Mice that died before 14 months were excluded in the analysis.  
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